Volume 29, Number 11—November 2023
Synopsis
Outbreak of Pandoraea commovens Infections among Non–Cystic Fibrosis Intensive Care Patients, Germany, 2019–2021
, Peter Menzel, Rolf Schwarzer, Solveigh Wiesener, Felix Schoenrath, Frank Klefisch, Miriam Stegemann, and Frieder Pfäfflin
Table 3
Antimicrobial susceptibilities of Pandoraea commovens isolates in an outbreak among non–cystic fibrosis intensive care patients, Germany, 2019–2021
| Antimicrobial drugs tested | MIC, mg/L | Breakpoints, mg/L |
|
|---|---|---|---|
| Susceptible | Resistant | ||
| Ampicillin |
>32 |
<2 |
>8 |
| Ampicillin/sulbactam |
<2 |
<2 |
>8 |
| Piperacillin |
8 to >128 |
<8 |
>16 |
| Piperacillin/tazobactam |
<1 to >128 |
<8 |
>16 |
| Temocillin |
>128 |
IE |
IE |
| Cefotaxime |
8–16 |
<1 |
>2 |
| Ceftazidime |
>64 |
<4 |
>8 |
| Cefepime |
>64 |
<4 |
>8 |
| Ceftolozane/tazobactam |
16 to >256 |
<4 |
>4 |
| Ceftazidime/avibactam |
16 to >256 |
<4 |
>8 |
| Cefiderocol |
>256 |
<2 |
>2 |
| Meropenem |
1–8 |
<2 |
>8 |
| Imipenem |
<0.25 to 1 |
<2 |
>4 |
| Imipenem/relebactam |
<1 |
<2 |
>2 |
| Ertapenem |
<0.5 to >8 |
<0.5 |
>0.5 |
| Aztreonam |
32 to >128 |
<4 |
>8 |
| Aztreonam/avibactam |
>128 |
NA |
NA |
| Ciprofloxacin |
>4 |
<0.25 |
>0.5 |
| Moxifloxacin |
>8 |
<0.25 |
>0.25 |
| Gentamicin |
8 to >16 |
<0.5 |
>0.5 |
| Tobramycin |
>16 |
<0.5 |
>0.5 |
| Amikacin |
>64 |
1 |
>1 |
| TMP/SXT |
<20 |
IE |
IE |
| Fosfomycin |
128 to >256 |
IE |
IE |
| Colistin |
>16 |
IE |
IE |
| Minocycline |
1–4 |
IE |
IE |
| Tigecycline |
1 |
<0.5 |
>0.5 |
| Doxycycline | >16 | IE | IE |
*MIC results are from susceptibility testing of 35 Pandoraea spp. isolates. The table comprises results of different test methods VITEK 2 (bioMérieux, https://www.biomerieux.com), MICRONAUT-S broth microdilution (MERLIN Diagnostika GmbH, https://www.merlin-diagnostika.de), and MIC strips (Liofilchem, https://www.liofilchem.com). IE, insufficient evidence, no breakpoints available; NA, not applicable; TMP/SXT, trimethoprim/sulfamethoxazole. †According to pharmacokinetic/pharmacodynamic (non–species related breakpoints from European Committee on Antimicrobial Susceptibility Testing Clinical Breakpoint Tables version 11.0, 2021 (http://www.eucast.org).